Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 11 |
| List of Tables | 9 | 4 |
| List of Figures | 13 | 4 |
| Introduction | 17 | 1 |
| GlobalData Report Guidance | 17 | 1 |
| Overview of Pharmaceutical and Medical Device Markets | 18 | 102 |
| Pharmaceutical Market | 18 | 1 |
| Market Overview | 18 | 6 |
| Pharmaceutical Imports and Exports | 24 | 1 |
| Supply Channels | 24 | 1 |
| Market Segments | 25 | 1 |
| Generic Drugs | 25 | 2 |
| Biologics/Biosimilars | 27 | 1 |
| Over-the-Counter Drugs | 27 | 2 |
| Major Therapeutic Areas | 29 | 1 |
| Cardiovascular Diseases | 29 | 1 |
| Cancer | 30 | 1 |
| Respiratory Disorders | 30 | 1 |
| Diabetes | 31 | 1 |
| Major Players | 32 | 1 |
| Julphar | 32 | 1 |
| Overview | 32 | 1 |
| Product Portfolio | 32 | 1 |
| Research and Development | 33 | 1 |
| SWOT Analysis | 33 | 4 |
| Neopharma | 37 | 1 |
| Overview | 37 | 1 |
| Product Portfolio | 38 | 1 |
| Research and Development | 39 | 1 |
| SWOT Analysis | 39 | 3 |
| Pfizer | 42 | 1 |
| Overview | 42 | 1 |
| Product Portfolio | 42 | 1 |
| Research and Development | 43 | 1 |
| SWOT Analysis | 44 | 6 |
| GlaxoSmithKline | 50 | 1 |
| Overview | 50 | 1 |
| Product Portfolio | 50 | 2 |
| Research and Development | 52 | 1 |
| SWOT Analysis | 53 | 5 |
| Novartis | 58 | 1 |
| Overview | 58 | 1 |
| Product Portfolio | 58 | 1 |
| Research and Development | 59 | 3 |
| SWOT Analysis | 62 | 6 |
| Medical Device Market | 68 | 1 |
| Market Overview | 68 | 1 |
| Overview of the Top Five Segments | 69 | 2 |
| In Vitro Diagnostics | 71 | 2 |
| Ophthalmic Devices | 73 | 1 |
| Orthopedic Devices | 74 | 2 |
| Drug Delivery Devices | 76 | 2 |
| Wound Care Management | 78 | 3 |
| Major Players | 81 | 1 |
| Medtronic | 82 | 1 |
| Overview | 82 | 1 |
| Product Portfolio | 83 | 1 |
| Research and Development | 84 | 1 |
| SWOT Analysis | 84 | 5 |
| Siemens Healthcare | 89 | 1 |
| Overview | 89 | 1 |
| Product Portfolio | 90 | 1 |
| Research and Development | 90 | 1 |
| SWOT Analysis | 90 | 5 |
| Roche | 95 | 1 |
| Overview | 95 | 1 |
| Product Portfolio | 96 | 1 |
| Research and Development | 96 | 1 |
| SWOT Analysis | 97 | 6 |
| Abbott Laboratories | 103 | 1 |
| Overview | 103 | 1 |
| Product Portfolio | 103 | 1 |
| Research and Development | 104 | 1 |
| SWOT Analysis | 104 | 5 |
| Boston Scientific | 109 | 1 |
| Overview | 109 | 1 |
| Product Portfolio | 110 | 1 |
| Research and Development | 110 | 1 |
| SWOT Analysis | 110 | 6 |
| Market Drivers and Barriers | 116 | 1 |
| Drivers | 116 | 2 |
| Barriers | 118 | 2 |
| Market Access | 120 | 33 |
| Reimbursement and Payer Landscape | 120 | 1 |
| Overview of Healthcare System | 120 | 1 |
| Reimbursement Process | 121 | 4 |
| Overview of Insurance Providers | 125 | 1 |
| Public Insurance | 125 | 1 |
| Private Insurance | 126 | 1 |
| Patient Share of Healthcare Expenditure | 127 | 1 |
| Healthcare Price Trends | 128 | 1 |
| Pricing Policies | 129 | 2 |
| Regulatory Landscape | 131 | 1 |
| Overview of Regulatory Agencies | 131 | 4 |
| Market Authorization Procedure for Pharmaceutical Products | 135 | 1 |
| Market Authorization Procedure for New Drugs | 135 | 2 |
| Market Authorization Procedure for Generic Drugs | 137 | 1 |
| New Medical Device Approval Process | 138 | 2 |
| Licensing Process for Pharmaceutical and Medical Device Manufacturing | 140 | 2 |
| Licensing Process for Pharmaceutical Exports and Imports | 142 | 1 |
| Intellectual Property Rights | 143 | 1 |
| Patents | 143 | 3 |
| Trademarks and Service Marks | 146 | 1 |
| Clinical Trial Regulations | 147 | 2 |
| Pharmaceutical Advertising Regulations | 149 | 1 |
| Pharmacy Regulations | 150 | 1 |
| Labeling and Packaging Regulations | 151 | 2 |
| Country Analysis | 153 | 72 |
| Political Environment | 153 | 1 |
| Political Structure | 153 | 1 |
| Analysis of the Current Political Environment | 154 | 2 |
| Healthcare Policy Initiatives | 156 | 4 |
| Economic Landscape | 160 | 4 |
| Economic Indicators | 164 | 1 |
| Gross Domestic Product | 164 | 1 |
| Gross Domestic Product per Capita | 164 | 2 |
| Annual Change in Gross Domestic Product | 166 | 3 |
| Gross National Income | 169 | 1 |
| Inflation | 170 | 1 |
| Consumer Price Index | 170 | 1 |
| Annual Change in Consumer Price | 171 | 1 |
| Currency Exchange Rate | 172 | 1 |
| Foreign Direct Investment | 173 | 1 |
| Foreign Exchange Reserves | 174 | 1 |
| Trade Balance | 175 | 1 |
| Imports of Goods and Services | 175 | 1 |
| Exports of Goods and Services | 176 | 1 |
| Government Net Debt | 177 | 1 |
| Major Industries | 178 | 2 |
| Demographics | 180 | 1 |
| Population | 180 | 2 |
| Urban Rural Share | 182 | 1 |
| Distribution by Age Group | 183 | 3 |
| Birth Rate | 186 | 1 |
| Mortality | 187 | 1 |
| Leading Causes of Mortality | 188 | 2 |
| Health Status by Gender and Age | 190 | 1 |
| Infant mortality | 190 | 1 |
| Immunization | 191 | 1 |
| Causes of Mortality in Males | 192 | 1 |
| Causes of Mortality in Females | 193 | 1 |
| Gender Ratio | 194 | 1 |
| Life Expectancy | 195 | 2 |
| Education and Literacy | 197 | 3 |
| Employment | 200 | 2 |
| Disease Burden | 202 | 2 |
| Healthcare Infrastructure | 204 | 1 |
| Healthcare Facilities | 204 | 1 |
| Public Private Hospitals | 205 | 2 |
| Beds by Specialty | 207 | 1 |
| Diagnostic Facilities | 208 | 2 |
| Healthcare Parameters | 210 | 1 |
| Hospital-Beds-to-Population Ratio | 210 | 1 |
| Doctor-to-Population Ratio | 211 | 1 |
| Environmental Health | 212 | 6 |
| Healthcare Personnel | 218 | 1 |
| Healthcare Expenditure | 219 | 1 |
| Overview of Healthcare Expenditure | 219 | 2 |
| Major Components of Healthcare Expenditure | 221 | 1 |
| Public and Private Sector Share | 222 | 1 |
| Spending in Pharmaceutical R&D | 223 | 1 |
| Trade Associations | 223 | 1 |
| Arab Union of Producers of Drugs and Medical Supplies | 223 | 1 |
| Emirates Medical Association | 223 | 1 |
| Pharmaceutical Research and Manufacturers Association Gulf | 223 | 1 |
| Gulf Pharmaceutical Industries Association | 223 | 1 |
| Middle East Medical Devices and Diagnostics Trade Association | 224 | 1 |
| Trade Fairs | 224 | 1 |
| Opportunities and Challenges | 225 | 3 |
| Opportunities | 225 | 1 |
| Challenges | 226 | 2 |
| Appendix | 228 | 24 |
| Abbreviations | 228 | 2 |
| Bibliography | 230 | 18 |
| Research Methodology | 248 | 3 |
| Coverage | 248 | 1 |
| Secondary Research | 249 | 1 |
| Forecasts | 250 | 1 |
| Expert Panel | 250 | 1 |
| Disclaimer | 250 | 2 |